Volta

A highly sensitive nanobody-based immunoassay detecting SARS-CoV-2 nucleocapsid protein using all-recombinant reagents

Unknown authors · 2023
hash_id: f76e562ca812b483c62d756086b3a8d5fe4138e7c9028e6f5c04b9f0c1059c9a · DOI: 10.3389/fimmu.2023.1220477

Antigen tests have been crucial for managing the COVID-19 pandemic by identifying individuals infected with SARS-CoV-2. This remains true even after immunity has been widely attained through natural infection and vaccination, since it only provides moderate protection against transmission and is highly permeable to the emergence of new virus variants. For this reason, the widespread availability of diagnostic methods is essential for health systems to manage outbreaks effectively. In this work, we generated nanobodies to the virus nucleocapsid protein (NP) and after an affinity-guided selection identified a nanobody pair that allowed the detection of NP at sub-ng/mL levels in a colorimetric two-site ELISA, demonstrating high diagnostic value with clinical samples. We further modified the assay by using a nanobody-NanoLuc luciferase …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (1)

Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection secondary